The Purpose of This Study is to Evaluate Efficacy and Safety of NT-101 Eye Drops in Patients With Wet Age-Related Macular Degeneration (AMD)

This study will consist of a 4-week screening, 12-week treatment, and 4-week follow-up. After completing screening procedures, approximately 66 eligible subjects will be randomized in a 1:1 ratio to receive 0.20 mM of NT-101 or placebo to be self-administered (or by a caregiver) two drops of NT-101 or placebo into the study eye twice daily for 12 weeks. Following the baseline visit, all study subjects will return to the clinic for study visit assessments at Weeks 4, 8, and 12. Subjects who discontinue early will complete an early termination visit for safety assessments. A follow-up will occur 4 weeks after the end of the treatment period (the last dose) and will include safety and efficacy assessments.

Clinical assessments include BCVA, slit-lamp examination, intraocular pressure (IOP) measurement, optical coherence tomography (OCT), indirect ophthalmoscopy/dilated fundus examination, fundus photography, and fundus fluorescein angiography (FFA). Adverse events (AEs) will be recorded at all study visits.

Inclusion criteria

• Subject who is male or female ≥ 50 years of age at Screening.
• CNV lesions secondary to AMD that affect the central subfield in the study eye that meet the following criteria at Screening:

• CNV lesions affect the fovea, as evidenced by fluorescein angiography in study eye.
• Intraretinal and/or subretinal fluid affecting the central subfield visible on OCT. If fluid is not visible due to previous treatment, earlier documented OCT images showing fluid for diagnosing wet AMD can be reviewed to fulfill this criterion.
• BCVA between 35 and 78 letters, inclusive, in the study eye at Screening using ETDRS testing, with BCVA decrement primarily attributable to wet AMD.
• Either no previous treatment in the study eye with anti-VEGF therapy (treatment naïve) or previously treated study eye with adequate washout from the baseline visit as defined below:

• Lucentis (ranibizumab): 30-day washout
• Avastin (bevacizumab): 30-day washout
• Eylea (aflibercept): 60-day washout
• Eylea (aflibercept) high dose 8mg: 70-day washout
• Vabysmo (faricimab-svoa): 70-day washout
• Biosimilars

• Byooviz (ranibizumab-nuna): 30-day washout
• Cimerli (ranibizumab-eqrn): 30-day washout
• Pavblu (aflibercept-ayyh): 60-day washout
• Afqlir (aflibercept): 60-day washout
• Enzeevu (aflibercept-abzv): 60-day washout
• Ahzantive (aflibercept-mrbb): 60-day washout
• Demonstrates the ability to instill eye drops (by the subject or caregiver) in the study eye, express willingness to comply with the dosing regimen, and commit to attending all study visits.
• Understands and voluntarily signs an informed consent form.
• Female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse, or agree to practice two acceptable methods of contraception throughout the course of the study and 3 months after their last study administration. Acceptable methods of contraception include:

• Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch, or vaginal ring),
• intrauterine device,
• barrier methods (diaphragm, condom) with spermicide, or
• surgical sterilization (hysterectomy or tubal ligation).

Exclusion criteria

• Subject who has the following illness or abnormal laboratory test values at

Screening:

• Uncontrolled hypertension (systolic > 180 mmHg or diastolic > 100 mmHg) despite optimal medical regimen
• Uncontrolled diabetes (HbA1c > 12.0%)
• Total bilirubin > 1.5 × Upper Limit of Normal (ULN)
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × ULN
• Prothrombin time (PT) > 1.5 × ULN
• Hemoglobin (Hb) < 10 g/dL (male); Hb < 9 g/dL (female)
• Platelets < 100 × 103 µL
• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
• Positive results for Human Immunodeficiency Virus (HIV) or Hepatitis B or C viruses.
• Other clinically significant abnormal lab values per Investigator's judgement.
• Subject who has a medical condition that, in the opinion of the Investigator, would preclude participation in the study (e.g., unstable medical status including psychiatric disorder, cardiovascular disease, poor glycemic control, and significant medical condition including end-stage renal disease and severe liver disease).
• History of stroke or myocardial infarction (MI) within 6 months prior to Screening.
• Subject who has had major surgery within 3 months prior to Screening.
• Pregnant or breastfeeding or intending to become pregnant during the study.
• Subject with known hypersensitivity to any active substance or excipients of the investigational product, fluorescein, dilating eye drops, or any of the anesthetic and antimicrobial drops.
• Treatment with investigational therapy or participation in any other type of interventional trial within 30 days before Screening.
• Subject who has a history of AMD treatment in the study eye with Beovu® (brolucizumab) or photodynamic therapy.
• CNV in the study eye secondary to other causes or subject who has an ocular condition (other than AMD) that, in the opinion of the Investigator, may limit visual acuity improvement during the course of the study (e.g., ocular histoplasmosis, trauma, pathological myopia, angioid streaks, choroidal rupture, multifocal choroiditis, congenital eye malformations, retinal pigment epithelial tear, or posterior uveitis, etc.).
• Media opacities or abnormalities in the study eye that would preclude visualization of the retina.
• Subject who has a history of retinal detachment or retinal detachment repair surgery in the study eye, unless otherwise allowed at the discretion of the Investigator.
• Subject who has a history of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to randomization in the study eye.
• Uncontrolled glaucoma in either eye (IOP > 25 mmHg despite treatment with a standard regimen of antiglaucoma medications), with exceptions allowed at the Investigator's discretion.
• Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in either eye on Screening.
• Subject who has a history of vitrectomy in the study eye, unless otherwise allowed at the discretion of the Investigator.
• Subject who has a history of ocular surgery in the study eye (including cataract extraction, any intraocular surgery, etc.) within 3 months prior to Screening or anticipated within the next 6 months following randomization.
• Subject who has any history of intraocular inflammation in either eye, other than what would be expected in the normal post-operative course following prior routine ocular surgery such as cataract surgery.
• Subject who has other retinal pathologies in the study eye that would interfere with vision, such as evidence of diabetic macular edema or diabetic retinopathy (defined as more than one microaneurysm).
• Non-study eye with a BCVA worse than 20 letters at Screening using ETDRS testing.
• Total lesion size >12 disc areas (30.5 mm2), including blood, scar, and neovascularization, in the study eye as assessed by FA.
• Scar, fibrosis, or atrophy involving the center of the fovea in the study eye, as assessed by FA.